Change search
ReferencesLink to record
Permanent link

Direct link
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
Columbia University College of Physicians and Surgeons, New York, NY, USA.
Antwerp University Hospital, Edegem, Belgium.
Hôspital Hotel-Dieu, Paris, France.
Hôpital Notre-Dame, Montréal (Qc) H2L 4M1, Canada.
Show others and affiliations
2011 (English)In: Gynecologic Oncology, ISSN 0090-8258, E-ISSN 1095-6859, Vol. 122, no 2, 350-355 p.Article in journal (Refereed) Published
Abstract [en]

Objectives: To evaluate in a large phase III recurrent ovarian cancer trial (OVA-301): 1) the concordance between CA-125 level vs. best overall response (OR) and progression-free survival (PFS) determined by radiological assessment 2) the impact of early CA-125 changes over the subsequent radiological response, and 3) the prognostic value of CA-125 response and CA-125 PFS to predict radiological response and PFS.

Methods: Assessment of response in the entire randomized population was performed by the Response Evaluation Criteria in Solid Tumors 1.0 (RECIST) and modified Rustin criteria for CA-125 determination.

Results: Most CA-125 decreases were observed in RECIST responders (82% of patients treated with the combination and 74% in the PLD alone). CA-125 progression preceded REC1ST progression in 35% of patients with a median lead time of 8.4 weeks. A high concordance rate between CA-125 PFS status at 4 months (PFS4) and CA-125 response as a predictor of PFS4 (87%) and radiological response (79%) was found in the combination, with high positive predictive value for radiological PFS4 (92%) and high negative predictive value for OR (90%). An early CA-125 decrease was predictive for the ultimate response since it was found in a high rate of RECIST responders.

Conclusion: Radiological response was preceded by a favorable predictive CA-125 decrease in a high proportion of patients, suggesting that CA-125 evaluation may be an appropriate tool for tumor assessment in patients with ovarian cancer.

Place, publisher, year, edition, pages
New York, 2011. Vol. 122, no 2, 350-355 p.
Keyword [en]
CA-125, Rustin criteria, Platinum, Relapsed ovarian cancer, Trabectedin
National Category
Cancer and Oncology
URN: urn:nbn:se:umu:diva-46692DOI: 10.1016/j.ygyno.2011.04.005PubMedID: 21546066OAI: diva2:440160
Available from: 2011-09-12 Created: 2011-09-09 Last updated: 2011-11-02Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Boman, Karin
By organisation
In the same journal
Gynecologic Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 79 hits
ReferencesLink to record
Permanent link

Direct link